AIDS Institute, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, PR China.
National Clinical Research Center for Infectious Diseases, HKU AIDS Institute Shenzhen Research Laboratory, The Third People's Hospital of Shenzhen and The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, PR China.
Cell Mol Immunol. 2022 Nov;19(11):1302-1310. doi: 10.1038/s41423-022-00924-8. Epub 2022 Oct 12.
Mutations in SARS-CoV-2 variants of concern (VOCs) have enhanced transmissibility and immune evasion with respect to current vaccines and neutralizing antibodies (NAbs). How naturally occurring spike mutations affect the infectivity and antigenicity of VOCs remains to be investigated. The entry efficiency of individual spike mutations was determined in vitro using pseudotyped viruses. BALB/c mice were immunized with 2-dose DNA vaccines encoding B.1.1.7, B.1.351, B.1.1.529 and their single mutations. Cellular and humoral immune responses were then compared to determine the impact of individual mutations on immunogenicity. In the B.1.1.7 lineage, Del69-70 and Del 144 in NTD, A570D and P681H in SD1 and S982A and D1118H in S2 significantly increased viral entry, whereas T716I resulted in a decrease. In the B.1.351 lineage, L18F and Del 242-244 in the NTD, K417N in the RBD and A701V in S2 also increased viral entry. S982A weakened the generation of binding antibodies. All sera showed reduced cross-neutralization activity against B.1.351, B.1.617.2 (Delta) and B.1.1.529 (Omicron BA.1). S982A, L18F, and Del 242-244 hindered the induction of cross-NAbs, whereas Del 69-70, Del144, R246I, and K417N showed the opposite effects. B.1.351 elicited adequate broad cross-NAbs against both B.1.351 and B.1.617.2. All immunogens tested, however, showed low neutralization against circulating B.1.1.529. In addition, T-cell responses were unlikely affected by mutations tested in the spike. We conclude that individual spike mutations influence viral infectivity and vaccine immunogenicity. Designing VOC-targeted vaccines is likely necessary to overcome immune evasion from current vaccines and neutralizing antibodies.
SARS-CoV-2 变体(VOCs)中的突变增强了其相对于当前疫苗和中和抗体(NAbs)的传染性和免疫逃逸能力。自然发生的刺突突变如何影响 VOC 的感染性和抗原性仍有待研究。使用假型病毒在体外确定单个刺突突变的进入效率。BALB/c 小鼠用编码 B.1.1.7、B.1.351、B.1.1.529 及其单个突变的 2 剂 DNA 疫苗免疫。然后比较细胞和体液免疫反应,以确定单个突变对免疫原性的影响。在 B.1.1.7 谱系中,NTD 中的 Del69-70 和 Del144、SD1 中的 A570D 和 P681H 以及 S2 中的 S982A 和 D1118H 显著增加了病毒进入,而 T716I 则导致减少。在 B.1.351 谱系中,NTD 中的 L18F 和 Del242-244、RBD 中的 K417N 和 S2 中的 A701V 也增加了病毒进入。S982A 削弱了结合抗体的产生。所有血清对 B.1.351、B.1.617.2(Delta)和 B.1.1.529(Omicron BA.1)的交叉中和活性均降低。S982A、L18F 和 Del242-244 阻碍了交叉 NAb 的诱导,而 Del69-70、Del144、R246I 和 K417N 则表现出相反的效果。B.1.351 对 B.1.351 和 B.1.617.2 均产生了足够广泛的交叉 NAb。然而,所有测试的免疫原对循环中的 B.1.1.529 的中和作用均较低。此外,刺突中的测试突变不太可能影响 T 细胞反应。我们得出结论,单个刺突突变影响病毒的感染性和疫苗的免疫原性。设计针对 VOC 的疫苗可能是克服当前疫苗和中和抗体免疫逃逸的必要手段。